Scientific programme
The livestream starts on 10 November 2022 at 16:00 CET
Thursday, 10 November 2022
16:00 – 16:10 CET
Welcome and Introduction
Schnell O (Munich, Germany)
Schnell O (Munich, Germany)
16:10 – 17:10 CET
Clinical guidelines on CVD, HF and diabetes: facilitating their development and implementation
Chair: Mathieu C (Leuven, Belgium), Rydén L (Stockholm, Sweden)
Chair: Mathieu C (Leuven, Belgium), Rydén L (Stockholm, Sweden)
16:10 – 16.25
Update on CVD, HF, and CKD Treatment: The ADA-EASD Consensus Report 2022
Mathieu C (Leuven, Belgium)
Mathieu C (Leuven, Belgium)
16:25 – 16:40
New pharmacotherapies for Type 2 Diabetes: a systematic review and network meta-analysis of randomised controlled trials
Mustafa R (Kansas City, US), Vandvik PO (Oslo, Norway)
Mustafa R (Kansas City, US), Vandvik PO (Oslo, Norway)
16:40 – 16:55
Diabetes and CVD: achieving guideline-recommended management at 12 months
Green J (Durham, US))
Green J (Durham, US))
16:55 – 17:10
Discussion
17:10 – 18:40 CET
Keynote symposium: From early developments to improved daily clinical care
Chair: Škrha J (Prague, Czech Republic), Forst T (Mannheim, Germany)
Chair: Škrha J (Prague, Czech Republic), Forst T (Mannheim, Germany)
17:10 – 17:30
Early Clinical Studies: Paving the road for outcomes trials in diabetes
Hompesch M (San Diego, US)
Hompesch M (San Diego, US)
17:30 – 17:40
Discussion
17:40 – 18:00
Subtypes of Type 2 Diabetes – Shaping cardiovascular risk
Birkenfeld A (Tuebingen, Germany)
Birkenfeld A (Tuebingen, Germany)
18:00 – 18:10
Discussion
18:10 – 18:30
CGM for changing Type 2 Diabetes medication
Bergenstal R (Minneapolis, US)
Bergenstal R (Minneapolis, US)
18:30 – 18:40
Discussion
18:40 – 19:00 CET
Break
19:00 – 20:00 CET
From evidence to practice in type 2 diabetes: How can we actually implement state-of-the-art care?
Chair: Kanumilli N (Manchester, UK), Cheng A (Mississauga, Canada)
Chair: Kanumilli N (Manchester, UK), Cheng A (Mississauga, Canada)
19:00 – 19:10
Why should we mind the intention-action gap in guideline implementation?
Kanumilli N (Manchester, UK)
Kanumilli N (Manchester, UK)
19:10 – 19:25
Deciphering guidelines – One voice on cardiorenal protection
Cheng A (Mississauga, Canada)
Cheng A (Mississauga, Canada)
19:25 – 19:40
Screening for CKD in PCP clinic
Rossing P (Copenhagen, Denmark)
Rossing P (Copenhagen, Denmark)
19:40 – 19:50
Never walk alone – Become a Guardian
Kanumilli N (Manchester, UK)
Kanumilli N (Manchester, UK)
19:50 – 20:00
Q&A, Summary and Closing
Cheng A (Mississauga, Canada)
Cheng A (Mississauga, Canada)
See you on Friday, 11 November 2022 at 08:30 CET
Friday, 11 November 2022
08:30 – 09:45 CET
Innovation and Implementation: Insulins, CGM and more
Chair: Schumm-Draeger P (Munich, Germany), Mankovsky B (Kyiv, Ukraine)
Chair: Schumm-Draeger P (Munich, Germany), Mankovsky B (Kyiv, Ukraine)
08:30 – 08:45
Further merging new glycemic markers with outcomes in diabetes
Battelino T (Ljubljana, Slovenia)
Battelino T (Ljubljana, Slovenia)
08:45 – 09:00
Combination therapy: When is the right time for insulin?
Giorgino F (Bari, Italy)
Giorgino F (Bari, Italy)
09:00 – 09:25
Inhaled Insulin: Initiation and titration to improve time in range
Pettus J (San Diego, US), Edelman S (San Diego, US)
Pettus J (San Diego, US), Edelman S (San Diego, US)
09:25 – 09:45
Discussion
09:45 – 10:30 CET
Real World Evidence (RWE): Shedding more light on the path to better clinical care
Chair: Topsever P (Istanbul, Turkey), Kanumili N (Manchester, UK)
Chair: Topsever P (Istanbul, Turkey), Kanumili N (Manchester, UK)
09:45 – 10:00
CKD: The importance of Real World Evidence (RWE) in clinical decision making
Pecoits-Filho R (Curitiba, Brasil)
Pecoits-Filho R (Curitiba, Brasil)
10:00 – 10:15
Real world evidence in CVD: strengths and weaknesses
Kanumili N (Manchester, UK)
Kanumili N (Manchester, UK)
10:15 – 10:25
Oral presentation: Risk of stroke in patients with Type 2 Diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: A real-world US claims database analysis
Evans M (Cardiff, UK)
Evans M (Cardiff, UK)
10:25 – 10:30
Discussion
10:30 – 11:00 CET
Break
11:00 – 12:30 CET
Recent advances in the management of CKD
Chair: Heerspink H (Groningen, Netherlands), Ji L (Beijing, China)
Chair: Heerspink H (Groningen, Netherlands), Ji L (Beijing, China)
11:00 – 11:15
Treatment of CKD: SGLT-2-inhibitors and future developments
Heerspink H (Groningen, Netherlands)
Heerspink H (Groningen, Netherlands)
11:15 – 11:30
GLP-1 RAs moving towards CKD: An update
Nauck M (Bochum, Germany)
Nauck M (Bochum, Germany)
CKD in diabetes: clinical and practical considerations for nonsteroidal MRAs
Chair: Heerspink H (Groningen, Netherlands), Rydén L (Stockholm, Sweden)
Chair: Heerspink H (Groningen, Netherlands), Rydén L (Stockholm, Sweden)
11:30 – 11:45
Management of CKD in diabetes - Targeting unmet needs
Groop PH (Helsinki, Finland)
Groop PH (Helsinki, Finland)
11:45 – 12:00
New treatment options for CKD in diabetes: Learnings from recent studies
Hadjadi S (Poitiers, France)
Hadjadi S (Poitiers, France)
12:00 – 12:30
Panel Discussion
12:30 – 13:00
Break
13:00 – 14:30 CET
Update on the management of heart failure
Chair: Izthak B (Tel Aviv, Israel), Standl E (Munich, Germany)
Chair: Izthak B (Tel Aviv, Israel), Standl E (Munich, Germany)
13:00 – 13:20
Monitoring and screening of heart failure in diabetes: The increasing role of biomarkers
Ceriello A (Milan, Italy)
Ceriello A (Milan, Italy)
13:20 – 13:40
Managing HFpEF with SGLT-2-inhibitors
Solomon S (Boston, US)
Solomon S (Boston, US)
13:40 – 13:50
Oral Presentation: Effectiveness and safety of empagliflozin in routine care: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Koeneman L (Bad Homburg, Germany)
Koeneman L (Bad Homburg, Germany)
13:50 - 14:00
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)
Ferrannini G (Stockholm, Sweden)
Ferrannini G (Stockholm, Sweden)
14:00 – 14:30 CET
Panel Discussion
14:30 – 15:00
Break
15:00 – 16:30 CET
Obesity and diabetes – In the midst of new treatment eras
Chair: Vilsbøll T (Copenhagen, Denmark), Rodbard H (Rockville, US)
Chair: Vilsbøll T (Copenhagen, Denmark), Rodbard H (Rockville, US)
15:00 – 15:20
Present and future of weight management in obesity and diabetes
Wilding JPH (Liverpool, UK)
Wilding JPH (Liverpool, UK)
15:20 – 15:40
Dual GIP/GLP Agonists: Guidelines and practical considerations in diabetes
Davies M (Leicester, UK)
Davies M (Leicester, UK)
15:40 – 16:00
Targeting obesity: High-dose GLP1-RAs and dual GIP/GLP Agonists
Vilsbøll T (Copenhagen, Denmark)
Vilsbøll T (Copenhagen, Denmark)
16:00 – 16:10
Oral Presentation: Systolic blood pressure reduction with tirzepatide across SURPASS program: A mediation analysis using weight loss as a factor
Ranta K (Indianapolis, US)
Ranta K (Indianapolis, US)
16:10 – 16:30
Discussion
16:30 – 17:30 CET
Industry´s perspective - panel discussion
17:30 – 18:30 CET
Oral Presentations
Chair: Standl E (Munich, Germany)
Chair: Standl E (Munich, Germany)
Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with Type 2 Diabetes
Rau M (Aachen, Germany)
Rau M (Aachen, Germany)
Influence of continuous glucose monitoring on the glycemic control and quality of life in patients with Type 2 Diabetes mellitus and coronary heart disease
Saienko Y (Kyiv, Ukraine)
Saienko Y (Kyiv, Ukraine)
Estimated glomerular filtration rate, mortality and MACE in men with hypogonadism and Type 2 Diabetes under long-term testosterone therapy
Saad F (Berlin, Germany)
Saad F (Berlin, Germany)
Investigating the role of small nucleolar RNAs (snoRNAs) as an early genetic marker of future adverse cardiovascular events
Kumar U (Cambridge, UK)
Kumar U (Cambridge, UK)
Plasma mannose as a novel marker of myocardial infarction across different glycaemic states
Fortin E (Stockholm, Sweden)
Fortin E (Stockholm, Sweden)
18:30 – 18:45 CET
Abstract Awards and Closing
Schnell O (Munich, Germany)
Schnell O (Munich, Germany)
Thank you for your attendance and your contribution to the Virtual CVOT Summit 2022. See you next year!